Advanced search
Publication Cover
Scandinavian Journal of Infectious Diseases Volume 23, 1991 - Issue sup78
Submit an article Journal homepage
88
Views
0
CrossRef citations to date
0
Altmetric
Miscellany

Patterns of Multi-Resistance and Their Clinical Significance

S. Ragnar Norrby
Pages 1-70 | Published online: 02 Jan 2015

References

  • Tipper DJ. Mode of action of β-lactam antibiotics. Pharmacol Ther 27: 1–35, 1985
  • Tomasz A. The mechanism of the irreversible antimicrobial effects of penicillin: How the beta-lactam antibiotics kill and lyze bacteria. Ann Rev Microbiol 33: 113–137, 1979
  • Malouin F, Bryan LE. Modification of penicillin-binding proteins as mechanisms of resistance. Antimicrob Agents Chemother 30: 1–5, 1986
  • Fontana R. Penicillin-binding proteins and the intrinsic resistance to beta-lactams in Gram-positive cocci. J Antimicrob Chemother 16: 412–416, 1985
  • Hayes MV, Orr DC. Mode of action of ceftazidime: Affinity for the penicillin-binding proteins of Escherichia coli K12, Pseudomonas aeruginosa and Staphylococcus aureus. J Antimicrob Chemother 12: 119–126, 1983
  • Dougherty TJ, Koller AE, Tomasz A. Penicillin-binding proteins of penicillin-susceptible and intrinsically-resistant Neisseria gonorhoeae. Antimicrob Agents Chemother 18: 730–737, 1980
  • Powell M, Livermore DM. Selection and transformation of non-β-lactamase mediated insusceptibility to β-lactams in Haemophilus influenzae: Lack of cross-resistance between carbapenems and other agents. J Antimicrob Chemother 26: 741–8, 1990
  • Ubakata K, Yamashita N, Konno M. Occurrence of a β-lactam-inducible penicillin-binding protein in methicillin-resistant staphylococci. Antimicrob Agents Chemother 27: 851–857, 1985
  • Bush K. Characterization of β-lactamases. Antimicrob Agents Chemother 33: 259–276 (in three parts), 1989
  • Livermore DM. Clinical significance of β-lactamase induction and stable derepression in Gram-negative rods. Eur J Clin Microbiol 6: 439–445, 1987
  • Lindberg F, Normark S. Contribution of chromosomal β-lactamases to β-lactam resistance in enterobacteria. Rev Infect Dis 8, Suppl. 3: 292–304, 1986
  • Rosselet A, Zimmermann W. Mutants of Pseudomonas aeruginosa with impaired β-lactamase inducibility and increased sensitivity to β-lactam antibiotics. J Gen Microbiol 76: 455–457, 1973
  • Yang Y, Livermore DM. Interactions of meropenem with Class I chromosomal β-lactamases. J Antimicrob Chemother 24, Suppl. A: 207–217, 1989
  • Yang Y, Livermore DM. Interactions of FCE 22101 with Class I β-lactamases. J Antimicrob Chemother 23, Suppl. C: 85–94, 1989
  • Kasai K. Antibacterial antagonism of β-lactam antibiotics in experimental infections. Chemotherapy (Basel) 32: 148–159, 1986
  • Wiedemann B. Genetic and biochemical basis of resistance of Enterobacteraceae to β-lactam antibiotics. J Antimicrob Chemother 18, Suppl. B: 31–38, 1986
  • Yang Y, Livermore DM. Activity of temocillin and other penicillins against β-lactamase-inducible and -stably derepressed enterobacteria. J Antimicrob Chemother 22: 299–306, 1988
  • Follath F, Costa E, Thommen A, Frei F, Burdeska A, Meyer J. Clinical consequences of development of resistance to third generation cephalosporins. Eur J Clin Microbiol 6: 446–450, 1987
  • Akova M, Yang Y, Livermore DM. Interactions of tazobactam with inducibly- and constitutively-expressed Class I β-lactamases. J Antimicrob Chemother 25: 199–208, 1990
  • Coleman K, Griffin RJ, Page JWJ, Upshon PA. In vitro evaluation of BRL42715, a novel β-lactamase inhibitor. Antimicrob Agents Chemother 33: 1580–1587, 1989
  • Mediros AA. β-Lactamases. Br Med Bull 40: 18–27, 1984
  • Jacoby GA, Carreras I. Activities of β-lactam antibiotics against Escherchia coli strains producing extended-spectrum β-lactamases. Antimicrob Agents Chemother 34: 858–862, 1990
  • Page JWJ, Farmer TH, Elson SW. Hyperproduction of TEM-1 β-lactamase by Escherichia coli strains. J Antimicrob Chemother 23: 160–161, 1989
  • Philippon A, Labia R, Jacoby GA. Extended spectrum β-lactamases. Antimicrob Agents Chemother 33: 1131–1136, 1989
  • Sirot D, Sirot J, Labia R, Morand A, Courvalin P, Darfeuille-Michaud A, Perroux R, Cluzel R. Transferable resistance to third-generation cephalosporins in clinical isolates of Klebsiella pneumoniae: Identification of CTX-1, a novel β-lactamase. J Antimicrob Chemother 20: 323–334, 1987
  • Yang Y, Wu P-J, Livermore DM. Biochemical characterization of a β-lactamase hydrolyzing penems and carbapenems from two Serratia marcescens isolates. Antimicrob Agents Chemother 34: 755–758, 1990
  • a Watanabe M, Iyobe S, Inone M, Mitsuhashi S. Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 35: 147–151, 1991
  • Nikaido H. Outer membrane barrier as a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 33: 1831–1836, 1989
  • Livermore DM. Penicillin-binding proteins, porins and outer membrane-permeability in carbenicillin-resistant and -susceptible Pseudomonas aeruginosa. J Med Microbiol 18: 261–709, 1984
  • Livermore DM, Williams RJ, Williams JD. In-vitro activity of MK0787 (N-formimidoyl thienamycin) against Pseudomonas aeruginosa and other Gram-negative rods and its stablity to their β-lactamases. J Antimicrob Chemother 8: 355–362, 1981
  • Livermore DM, Yang Y. Comparative activity of meropenem against Pseudomonas aeruginosa strains with well-characterized resistance mechanisms. J Antimicrob Chemother 24, Suppl. A: 149–159, 1989
  • Quinn JP, Dudek EJ, Divencenzo CA, Lucks DA, Lerner SA. Emergence of resistance to imipenem during therapy for Pseudomonas aeruginosa infections. J Infect Dis 154: 289–294, 1986
  • Trias J, Nikaido H. Outer membrane protein D2 catalyzes facilitated diffusion of carbapenems and penems through the outer membrane of Pseudomonas aeruginosa. Antimicrob Agents Chemother 32: 52–58, 1990

References

  • Sanders CC. Novel resistance selected by the new expanded spectrum cephalosporins: A concern. J Infect Dis 147: 585–589, 1983
  • Marchou B, Michéa-Hamzehpour M, Lucain C, Pechère JC. Development of β-lactam-resistant Enterobacter cloacae in mice. J Infect Dis 156: 369–373, 1987
  • Pechère JC, Marchou B, Michéa-Hamzehpour M, Auckenthaler R. Emergence of resistance after therapy with antibiotics used alone or combined in a murine model. J Antimicrob Chemother 17 ( Suppl. A): 11–18, 1986
  • Pechère JC. Emergence of resistance during β-lactam therapy of Gram-negative infections: Bacterial mechanisms and medical responses. Drugs 35 ( Suppl. 2): 22–28, 1988
  • Milatovic D, Braveny I. Development of resistance during antibiotic therapy. Eur J Clin Microbiol 6: 234–244, 1987
  • Marchou B, Bellido F, Charnas R, Lucain C, Pechère JC. Contribution of β-lactamase hydrolysis and outer membrane permeability to ceftriaxone resistance in Enterobacter cloacae. Antimicrob Agents Chemother 31: 1589–1595, 1987
  • Seeberg AH, Tolxdorff-Neutzling RM, Wiedeman B. Chromosomal β-lactamases of Enterobacter cloacae are responsible for resistance to third generation cephalosporins. Antimicrob Agents Chemother 23: 918–925, 1983
  • Vu H, Nukaido H. Role of β-lactam hydrolysis in the mechanism of resistance of a β-lactamase. Constitutive Enterobacter cloacae strain to expanded spectrum β-lactams. Antimicrob Agents Chemother 27: 393–398, 1985
  • Livermore DM, Riddle SJ, Davy KWM. Hydrolytic model for cefotaxime and ceftriaxone resistance in β-lactamase derepressed Enterobacter cloacae. J Infect Dis 153: 619–620, 1986
  • Aronoff SC, Shlaes DM. Factors that influence the evolution of β-lactam resistance in β-lactamase inducible strains of Enterobacter cloacae and Pseudomonas aeruginosa. J Infect Dis 155: 936–941, 1987
  • Sawai T, Hiruma R, Kawana N, Kaneko M, Tanigasu F, Inami A. Outer membrane permeation of β-lactam antibiotics in Escherichia coli, Proteus mirabilis and Enterobacter cloacae. Antimicrob Agents Chemother 22: 585–592, 1982
  • Kaneko M, Yamaguchi A, Sawai T. Purification and characterisation of two kinds of porins from the Enterobacter cloacae outer membrane. J Bacteriol 158: 1179–1181.
  • Werner V, Sanders CC, Sanders Jr WE, Goering RV. Role of β-lactamases and outer membrane proteins in multiple β-lactam resistance of Enterobacter cloacae. Antimicrob Agents Chemother 27: 455–459, 1985
  • Hiraoka M, Inoue M, Mitsuhashi S. Hydrolytic rate at low drug concentration as a limiting factor in resistance to newer cephalosporin. Rev Infect Dis 10: 746–751, 1988
  • Sawai T, Yamaguchi A, Hiruma. Effect of interaction between outer membrane permeability and β-lactamase production on resistance to β-lactam agents in Gram-negative bacteria. Rev Infect Dis 10: 761–764, 1988
  • Yoshimura F, Nikaido H. Diffusion of β-lactam antibiotics through the porin channels of Escherichia coli K-12. Antimicrob Agents Chemother 27: 84–92, 1985
  • Trias J, Nikaido H. Outer membrane protein D2 catalyzes facilitated diffusion of carbapenems and penems through the outer membrane of Pseudomonas aeruginosa. Antimicrob Agents Chemother 34: 52–57, 1990
  • Hackbarth CJ, Chambers HF. Methicillin-resistant staphylococci: Genetics and mechanisms of resistance. Antimicrob Agents Chemother 33: 991–994, 1989
  • Malouin F, Bryan LE. Modification of penicillin-binding proteins as mechanisms of beta-lactam resistance. Antimicrob Agents Chemother 30: 1–5, 1986
  • Nikaido H, Normark S. Sensitivity of Escherichia coli to various β-lactams is determined by the interplay of outer membrane permeability and degradation by periplasmic β-lactamases: A quantitative predictive treatment. Molecular Microbiol 1: 29–36, 1987

References

  • Kresken M, Wiedemann B. Development of resistance in the past decade in central Europe. J Antimicrob Chemother 18, Suppl C: 235–242, 1986
  • Rosenthal EJ. Septikämie-Erreger 1983–1985. Ergebnisse einer multizentrischen Studie. Dtsch Med Wochenschr 111: 1874–1880, 1986
  • National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Standard M7-A2 1990 NCCLS, Villanova, PA
  • Lindberg F, Normark S. Contribution of chromosomal β-lactamases to β-lactam resistance in enterobacteria. Rev Infect Dis 8, Suppl 3: 292–304, 1986
  • Williams H, King A, Shannon K, Phillips I. Amoxycillin/clavulanate resistant Escherichia coli. Lancet i: 304–305, 1988
  • Martinez JL, Vicente MF, Delgado-Iribarren A, Perez-Diaz JC, Baquero F. Small plasmids are involved in amoxicillin-clavulanate resistance in Escherichia coli. Antimicrob Agents Chemother 33:595, 1989
  • Knothe H, Shah P, Krcmery V, Antal M, Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 11: 315–317, 1983
  • Sirot D, Sirot J, Labia R, Morand A, Courvalin P, Darfeuille-Michaud A, Perroux R, Cluzel R. Transferable resistance to third-generation cephalosporins in clinical isolates of Klebsiella pneumoniae: Identification of CTX-1, a novel β-lactamase. J Antimicrob Chemother 20: 323–334, 1987
  • Jacoby GA, Medeiros AA, O'Brien TF, Pinto ME, Jiang H. Broad-spectrum, transmissible beta-lacta-mases. N Engl J Med 319: 723–724, 1988
  • Williams RJ, Yang YJ, Livermore DM. Mechanisms by which imipenem may overcome resistance in Gram-negative bacilli. J Antimicrob Chemother 18, Suppl E: 9–13, 1986
  • Buscher KH, Cullmann W, Dick W, Opferkuch W. Imipenem resistance in Pseudomonas aeruginosa resulting from diminished expression of an outer membrane protein. Antimicrob Agents Chemother 31: 703–708, 1987
  • Kresken M, Jansen A, Wiedemann B. Prevalence of resistance of aerobic Gram-negative bacilli to broad-spectrum antibacterial agents: Results of a multicentre study. J Antimicrob Chemother 25: 1022–1024, 1990
  • Follath F, Costa E, Thommen A, Frei R, Burdeska A, Meyer J. Clinical consequences of development of resistance to third generation cephalosporins. Eur J Clin Microbiol 6: 446–450, 1987
  • Dworzack DL, Pugsley MP, Sanders CC, Horowitz EA. Emergence of resistance in Gram-negative bacteria during therapy with expanded-spectrum cephalosporins. Eur J Clin Microbiol 6: 456–459, 1987

References

  • Follath F . Clinical consequences of development of resistance to third generation cephalosporins. Eur J Clin Microbiol 6: 446–450, 1987
  • Tierno PM. Surveillance studies of multiresistance. In: Weinstein RA, Quinn JP, eds. Antibiotic-resistant infections: origin, treatment, control. New York: HP Publishing, 23–27, 1989
  • Livermore DM. Resistance to β-lactams and β-lactamase induction. In: Current topics in infectious diseases and clinical microbiology, vol. 3, 1990

References

  • Verbist L. Multicentre in vitro study of piperacillin. Acta Clin Belg 40: 22–26, 1985
  • Verbist L. A Belgian multicentre in-vitro study of ofloxacin. J Antimicrob Chemother 22: 35–43, 1988

References

  • National Nosocomial Infection Surveillance. Centers for Disease Control 35 ( S155): 17–24, 1989
  • Hughes JM. Epidemiology and prevention of nosocomial pneumonia. In: Remington JS, Swartz MN, ed. Current clinical topics in infectious diseases. New York: McGraw-Hill, 1988
  • Follath F, Costa E, Thommen A, Frei R, Burdeska A, Meyer J. Clinical consequences of development of resistance to third generation cephalosporins. Eur J Clin Microbiol 6: 446–450, 1987
  • Sanders Jr WE, Sanders CL. Inducible β-lactamases: Clinical and epidemiologic implications for use of newer cephalosporins. Rev Infect Dis 10: 830–838, 1988
  • Brown Jr BW, Hollander M. Statistics. A biomedical introduction. New York: John Wiley and Sons, 1977, 261–292
  • Quinn JP, Dudek EJ, Divencenzo CA, Lucks DA, Lerner SA. Emergence of resistance to imipenem during therapy for Pseudomonas aeruginosa infections. J Infect Dis 154: 289–294, 1986
  • Kahan FS, Guerriero S, and 1989 ICU surveillance study participants. Analysis of pooled results from the 1989 MSD-sponsored surveillance study of multiresistance in Gram-negative aerobes from intensive care units. Presented at the Third International Conference on Nosocomial Infections, Atlanta, GA, August 1990
  • Shah PM. Incidence of multiresistance in Gram-negative aerobes from intensive care units of 10 German hospitals. Scand J Infect Dis (in press).
  • Verbist LMF. Incidence of multiresistance in Gram-negative aerobes from intensive care units of 16 hospitals in Belgium: Results of a surveillance study. Scand J Infect Dis (in press).
  • Livermore DM. Clinical significance of beta-lactamase induction and stable derepression in Gram-negative rods. Eur J Clin Microbiol 6: 439–445, 1987
  • Dworzak DL, Pugsley MP, Sanders CC, Horowitz EA. Emergence of resistance in Gram-negative bacteria during therapy with extended-spectrum Cephalosporins. Eur J Clin Microbiol 6: 456–459, 1987
  • Phillips I. Discussion in session 5. Prevalence and clinical importance of class I β-lactamases. Rev Infect Dis 10: 839–847, 1988
  • Chow JW, Fine MJ, Johnson M, Hooper DC, Quinn JP, Shlaes DM, Rampal R, Yu VL. Enterobacter bacteremia: A multicenter study of 136 cases. Abstract 780 presented at the 29th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Houston, Texas, October 1989
  • Cornick NA, Cuchural Jr GJ, Snydman DR, Jacobus NV, Ianinni P, Hill G, Cleary T, O'Keefe JP, Pierson C, Finegold SM. The antimicrobial susceptibility patterns of the bacteroides fragilis group in the United States, 1987. J Antimicrob Chemother 25: 1011–1019, 1990

References

  • Love LJ, Schimpff SC, Schiffer CA, Wiernik PH. Improved prognosis for granulocytopenic patients with Gram-negative bacteremia. Am J Med 68: 643–648, 1980
  • Young LS. Combination or single drug therapy for gram-negative sepsis. In: Remington JS, Swartz MN, eds. Current clinical topics in infectious diseases. New York: McGraw-Hill, 1982, Vol. 3, 177–205
  • Gaya H. Rational basis for the choice of regimens for empirical therapy of sepsis in granulocytopenic patients. Schweiz Med Wochenschr 113 ( Suppl. 14): 49–57, 1983
  • Greenwood D. In vitro veritas? Antimicrobial tests and their clinical relevance. J Infect Dis 144: 380–385, 1981
  • Norrby SR. Antibiotic treatment: Relationship between pharmacokinetics, bacterial sensitivity, and dose schedules. In: Bearn AG, ed. Antibiotics in the management of infections: Outlook for the 1980s. New York: Raven Press, 1982, 61–80
  • The Swedish Reference Group for Antibiotics. A revised system for antibiotic sensitivity testing. Scand J Infect Dis 13: 148–152, 1981
  • Performance standards for antimicrobial disk susceptibility tests. Approved standard M2–A3. National Committee for Clinical Laboratory Standards (NCCLS) 4, SNo. 16, 1984
  • Methoden zur Empfindlichkeitsprüfung von bakteriellen Krankheitserregern (ausser Mykobakterien) gegen Chemotherapeutika. Deutsches Institut für Normung (DIN) 58, 940, 1981
  • Working Party of the British Society for Antimicrobial Chemotherapy (BASC). Break-points in in vitro sensitivity testing. J Antimicrob Chemother 21: 701–710, 1988
  • Bacquero F. European Standards for antibiotic susceptibility testing: Towards a theoretical consensus. Eur J Clin Microbiol Infect Dis 9: 492–494, 1990
  • Bacquero F, Reig M. Mechanisms of antimicrobial resistance in anaerobic bacteria: The predictive approach. Scand J Infect Dis, Suppl. 62: 25–28, 1989
  • Swedish Study Group. Therapy of acute and chronic Gram-negative osteomyelitis with ciprofloxacin. J Antimicrob Chemother 22: 221–228, 1988
  • Clissold SP, Todd PA, Campoli-Richards DM. Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 33: 183–241, 1987
  • Campoli-Richards DM, Monk JP, Price A, Benfield P, Todd PA, Ward A Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 35: 373–447, 1988
  • Blumer JL, Stern RC, Klinger JD, Yamashita TS, Meyers CM, Blum A, Reed MD. Ceftazidime therapy in patients with cystic fibrosis and multiply-drug-resistant pseudomonas. Am J Med 79 ( Suppl. 2A): 37–46, 1985
  • Sanders WE Jr, Sanders CC. Inducible β-lactamases: Clinical and epidemiological implications for use of newer cephalosporins. Rev Infect Dis 10: 830–838, 1988
  • Lindberg F, Normark S. Contribution of chromosomal β-lactamases to β-lactam resistance in enterobacteria. Rev Infect Dis 8 ( Suppl. 3): 292–304
  • Sirot J, Chanal C, Petit A, Labia R, Gerbaud G. Klebsiella pneumoniae and other Enterobacteriaceae producing novel plasmid-mediated β-lactamases markedly active against third-generation cephalosporins: Epidemiological studies. Rev Infect Dis 10: 850–859, 1988
  • Gutmann L. Kitzis MD, Billot-Klein D, Goldstein F, Tran Van Nhieu G, Lu T, Carlet J, Collatz E, Williamson R. Plasmid-mediated β-lactamase (TEM-7) involved in resistance to ceftazidime and aztreonam. Rev Infect Dis 10: 860–866, 1988
  • Norrby SR, Vandercam B, Louie T, Runde V, Norberg B, Anniko M, Andrien F, Baudrihaye M, Bow E, Burman LÅ, Bury J, Ezzedine H, Gigi J, Granlund M, Holm J, Lundberg S, Micheaux JL, le Saux N, Wahlin A, Zakrisson E. Imipenem/cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenic patients: A prospective randomized study. Scand J Infect Dis, Suppl. 52: 67–78, 1987
  • Patton WM, Smith GM, Leyland MJ, Geddes AM. Multiply resistant Salmonella typhimurium septicaemia in an immunocompromised patient successfully treated with ciprofloxacin. J Antimicrob Chemother 16: 667–669, 1985
  • Connolly MJ. Snow MH, Ingham HR. Ciprofloxacin treatment of recurrent Salmonella typhimurium septicaemia in a patient with acquired immunodeficiency syndrome. J Antimicrob Chemother 18: 647–648, 1986
  • Norrby R. A review of the penetration of antibiotics into CSF and its clinical significance. Scand J Infect Dis, Suppl. 14: 296–309, 1978
  • Cherubin CE. Eng RHK, Norrby R, Modai J, Humbert G, Overturf G. Penetration of newer cephalosporins into cerebrospinal fluid. Rev Infect Dis 11: 526–547, 1989
  • Swedish Study Group. Cefuroxime versus ampicillin and chloramphenicol for the treatment of bacterial meningitis. Lancet i: 295–299, 1982
  • Scandinavian Study Group. Imipenem/cilastatin versus gentamicin/clindamycin for treatment of serious bacterial infections. Lancet i: 868–871, 1984
  • Burman LÅ, Norrby R, Trollfors B. Invasive pneumococcal infections: Incidence, predisposing factors, and prognosis. Rev Infect Dis 7: 133–141, 1985
  • Saito H, Elting L, Bodey GP, Berkey P. Serratia bacteremia: Review of 118 cases. Rev Infect Dis 11: 912–920, 1989
  • Moore RD, Smith CR, Lipsky JJ, Mellitis EA, Lietman PS. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med 100: 352–357, 1984

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.